Galapagos NV has suffered another pipeline setback with its osteoarthritis (OA) asset GLPG1972, partnered with Servier, failing to produce any signal of activity in a mid-stage trial.
The Belgian biotech has issued topline results from the Phase II ROCELLA trial which evaluated three once-daily oral doses of...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
